Ruiz-Villaverde, RicardoRivera-Izquierdo, MarioGil-Villalba, AnaPegalajar-Garcia, Maria DPerez-Rojas, JavierSoler-Iborte, EvaValero-Ubierna, M Carmen2023-05-032023-05-032022-06-15Ruiz‐Villaverde R, Rivera‐Izquierdo M, Gil‐Villalba A, Pegalajar‐García MD, Pérez‐Rojas J, Soler‐Iborte E, et al. Dermatological adverse reactions after vaccination with BNT162b2 in a cohort of healthcare workers. International Journal Of Dermatology. 30 de junio de 2022;61(10):1289-93http://hdl.handle.net/10668/19967The description of the skin reactions produced by the different vaccines against SARS-CoV-2 has focused on the symptoms reported by the general population. There are few studies with very different measurement methods focused on healthcare workers. A longitudinal observational study was conducted on all the healthcare workers from the Hospital Universitario San Cecilio that received vaccination against COVID-19 with BNT162b2. The recruitment period was from December 2020 to September 2021. The recommended regimen was double, with a minimum interval of 21 days between doses. All dermatological reactions reported as adverse effects of the vaccine were evaluated by the Staff of the Dermatology Unit of our center. A total of 3969 healthcare workers of our center were followed. Only 0.7% of them reported dermatological adverse reactions. The most frequently reported reactions were morbilliform rash and COVID arm. In the multivariate analysis, the vaccination regimen (one dose) and the history of COVID-19 infection remained the main factors associated with the report of dermatological adverse reactions. The rate of dermatological adverse reactions after vaccination with BNT162b2 (Pfizer-BioNTech) is extraordinarily low. No patient required hospitalization, which supports the safety of this vaccination in a population of healthcare workers.enAnálisis multivarianteDermatologíaExantemaInfeccionesBNT162 VaccineCOVID-19COVID-19 VaccinesHealth PersonnelHumansSARS-CoV-2VaccinationVaccinesresearch article35775137Restricted AccessPacientesSARS-CoV-2Vacuna BNT162Vacunación10.1111/ijd.163361365-4632PMC9349676https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349676https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349676/pdf